Neuroprotective and neurorestorative strategies for parkinson’s disease

Nature Neuroscience

Volumn 5, Issue 11s, 2002, Pages 1058-1061

  Dawson, Ted M ^a   Dawson, Valina L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN INHIBITOR; CASPASE INHIBITOR; CHELATING AGENT; DOPAMINE UPTAKE INHIBITOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MINOCYCLINE; MIXED LINEAGE KINASE; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NITRIC OXIDE SYNTHASE; PROTEIN P53; PROTEIN P53 INHIBITOR; UBIDECARENONE; UNCLASSIFIED DRUG;

CELL DEATH; DEGENERATION; FAMILIAL DISEASE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW;

ANIMALS; ANTIPARKINSON AGENTS; BRAIN; CALCIUM-BINDING PROTEINS; DISEASE MODELS, ANIMAL; DRUG DESIGN; HUMANS; MEMBRANE PROTEINS; MITOCHONDRIA; MUSCLE PROTEINS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; RECOVERY OF FUNCTION;

EID: 0036829946     PISSN: 10976256     EISSN: 15461726     Source Type: Journal    
DOI: 10.1038/nn941     Document Type: Review

References (35)

1. Lang, A. E. & Lozano, A. M. Parkinson’s disease. First of two parts. N. Engl. J. Med. 339, 1044-1053 (1998).
2. Lang, A. E. & Lozano, A. M. Parkinson’s disease. Second of two parts. N. Engl. J. Med. 339, 1130-1143 (1998).
3. Dawson, T. M., Mandir, A. S. & Lee, M. K. Animal models of PD: pieces of the same puzzle? Neuron 35, 219-222 (2002).
4. Mizuno, Y., Hattori, N., Mori, H., Suzuki, T. & Tanaka, K. Parkin and Parkinson’s disease. Curr. Opin. Neurol. 14, 477-482 (2001).
5. Polymeropoulos, M. H. Genetics of Parkinson’s disease. Ann. NY Acad. Sci. 920, 28-32 (2000).
6. Dunnett, S.B. & Bjorklund, A. Prospects for new restorative and neuroprotective treatments in Parkinson’s disease. Nature 399, A32-A39 (1999).
7. Chung, K. K., Dawson, V. L. & Dawson, T. M. The role of the ubiquitin-proteasomal pathway in Parkinson’s disease and other neurodegenerative disorders. TrendsNeurosci. 24 (Suppl.), S7-S14 (2001).
8. Lavedan, C., Buchholtz, S., Nussbaum, R. L., Albin, R. L. & Polymeropoulos, M. H. A mutation in the human neurofilament M gene in Parkinson’s disease that suggests a role for the cytoskeleton in neuronal degeneration. Neurosci. Lett. 322, 57-61 (2002).
9. Trojanowski, J. Q., Goedert, M., Iwatsubo, T. & Lee, V. M. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson’s disease and Lewy body dementia. Cell Death Differ. 5, 832-837 (1998).
10. Zhang, Y., Dawson, V. L. & Dawson, T. M. Oxidative stress and genetics in the pathogenesis of Parkinson’s disease. Neurobiol. Dis. 7, 240-250 (2000).
11. Beal, M. F. Experimental models of Parkinson’s disease. Nat. Rev. Neurosci. 2, 325-334 (2001).
12. Betarbet, R. et al. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat. Neurosci. 3, 1301-1306 (2000).
13. Goedert, M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2, 492-501 (2001).
14. Galvin, J. E., Lee, V. M. & Trojanowski, J. Q. Synucleinopathies: clinical and pathological implications. Arch. Neurol. 58, 186-190 (2001).
15. Xu, J. et al. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8, 600-606 (2002).
16. Lansbury, P. T. & Brice, A. Genetics of Parkinson’s disease and biochemical studies of implicated gene products. Curr. Opin. Genet. Dev. 12, 299-306 (2002).
17. Conway, K. A., Rochet, J. C., Bieganski, R. M. & Lansbury, P. T. Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294, 1346-1349 (2001).
18. Hashimoto, M., Rockenstein, E., Mante, M., Mallory, M. & Masliah, E. Beta-synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 32, 213-223 (2001).
19. Uversky, V. N. et al. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J. Biol. Chem. 277, 11970-11978 (2002).
20. Auluck, P. K., Chan, H. Y., Trojanowski, J. Q., Lee, V. M. & Bonini, N. M. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson’s disease. Science 295, 865-868 (2002).
21. Muqit, M. M. & Feany, M. B. Modelling neurodegenerative diseases in Drosophila: a fruitful approach? Nat. Rev. Neurosci. 3, 237-243 (2002).
22. Lee, M. K. et al. Human alpha-synuclein-harboring familial Parkinson’s disease-linked Ala-53-Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. USA99, 8968-8973 (2002).
23. Wolfe, M. S. Secretase as a target for Alzheimer’s disease. Curr. Top. Med. Chem. 2, 371-383 (2002).
24. Fujiwara, H. et al. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160-164 (2002).
25. Imai, Y. et al. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 105, 891-902 (2001).
26. Gash, D. M., Zhang, Z. & Gerhardt, G. Neuroprotective and neurorestorative properties of GDNF. Ann. Neurol. 44, S121-S125 (1998).
27. Kordower, J. H. et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson’s disease. Science 290, 767-773 (2000).
28. Bjorklund, A. & Lindvall, O. Parkinson disease gene therapy moves toward the clinic. Nat. Med. 6, 1207-1208 (2000).
29. Mayor, S. New treatment improves symptoms of Parkinson’s disease. BMJ 324, 997 (2002).
30. Date, I. et al. Grafting of encapsulated genetically modified cells secreting GDNF into the striatum of parkinsonian model rats. Cell Transplant. 10, 397-401 (2001).
31. McKay, R. Building animals from stem cells. Ann. NY Acad. Sci. 961, 44 (2002).
32. Rossi, F. & Cattaneo, E. Opinion: neural stem cell therapy for neurological diseases: dreams and reality. Nat. Rev. Neurosci. 3, 401-409 (2002).
33. Dunnett, S. B., Bjorklund, A. & Lindvall, O. Cell therapy in Parkinson’s disease—stop or go? Nat. Rev. Neurosci. 2, 365-369 (2001).
34. Bjorklund, L. M. et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc. Natl. Acad. Sci. USA99, 2344-2349 (2002).
35. Kim, J. H. et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson’s disease. Nature 418, 50-56 (2002).